Juq-097

| Issue | Recommendation | |-------|----------------| | Dosing | Start 30 mg PO once daily; titrate to 60 mg after 2 weeks if tolerable and craving persists. | | Monitoring | Baseline LFTs (ALT/AST), periodic CBC (rare neutropenia). Check mood scales (PHQ‑9) at weeks 4, 8, 12. | | Drug Interactions | Caution with strong CYP3A4 inhibitors (ketoconazole) – may increase exposure ~1.5×. Adjust dose if necessary. | | Contra‑indications | Severe hepatic impairment (Child‑Pugh C) – insufficient data. | | Special Populations | No pediatric data; pregnant‑lactation studies pending – avoid until safety established. | | Adjunctive Therapy | Combine with evidence‑based psychosocial interventions (CBT, mutual‑help groups). |

| Model | Key Findings | Translational Insight | |-------|--------------|-----------------------| | Alcohol‑preferring (P‑rats) | 60 % reduction in lever‑pressing for ethanol after 7 days of 30 mg/kg PO dosing. | Suggests robust anti‑craving effect. | | Stress‑induced reinstatement (mouse) | Blocked cue‑ and stress‑triggered reinstatement of cocaine seeking (p < 0.001). | Supports broader addiction applicability. | | Forced‑swim test (FST) | Dose‑dependent reduction in immobility time (≈ 30 % at 10 mg/kg). | Indicative of antidepressant‑like activity. | | Chronic pain (SNI model) | Prevented development of opioid‑induced hyperalgesia when co‑administered with morphine. | Potential adjunct for opioid stewardship. | | Safety/Tox | No QTc prolongation; NOAEL = 150 mg/kg/day (rat) with clean hepatic panel. | Favorable safety margin for human dosing. |

Pharmacokinetics (rat):

| System | Observations (Phase I/II) | |--------|---------------------------| | GI | Mild nausea (≤ 8 %); transient dyspepsia; no dose‑limiting events. | | CNS | Headache (10 %); occasional dizziness (4 %); no sedation or cognitive impairment. | | Cardiac | No QTc > 460 ms; routine ECGs unchanged. | | Hepatic | ALT/AST ≤ 1.2 × ULN; no bilirubin spikes. | | Psychiatric | No emergence of suicidal ideation; PHQ‑9 scores improved. | | Drug‑Drug Interactions | Minimal effect on warfarin INR; modest (≤ 15 %) increase in rosuvastatin AUC—monitor if co‑prescribed. | | Abuse Potential | In a “self‑administration” study, subjects did not increase dosing beyond prescribed; no reinforcing effects on VAS. |

Overall, JUQ‑097 appears well‑tolerated up to 60 mg qd, with a safety profile comparable to or better than existing AUD pharmacotherapies. JUQ-097

| Item | Details | |------|----------| | Generic/Code name | JUQ‑097 (also referenced in some filings as JQ‑097). | | Developer | Janssen Pharmaceuticals (J&J) – the “JUQ” prefix follows Janssen’s internal naming convention for early‑stage CNS‑focused small‑molecule programs. | | Chemical class | Highly selective, non‑peptidic antagonist of the nociceptin/orphanin‑FQ peptide (NOP) receptor (also known as OPRL1). | | Molecular weight | ≈ 420 Da (exact value pending final publication). | | Formulation | Oral tablets (10 mg, 30 mg, 60 mg) for Phase II/III trials; a soluble‑capsule version is in pre‑clinical toxicology. | | Target indication(s) | Alcohol Use Disorder (AUD) and Major Depressive Disorder (MDD) with comorbid alcohol misuse. Secondary exploratory programs include opioid‑induced hyperalgesia and post‑traumatic stress disorder (PTSD). |

Bottom line: JUQ‑097 is the first selective NOP‑receptor antagonist to advance beyond Phase I, positioning itself as a potential disease‑modifying therapy for disorders where dysregulated nociceptin signaling contributes to stress‑related relapse and craving. | Model | Key Findings | Translational Insight

JUQ-097 is presented here as a neutral, informational subject label. This document outlines plausible contexts, properties, development considerations, and recommended next steps for an item referenced by that code, suitable for use in technical reports, project proposals, or research briefs.

"JUQ-097" is a title released under the Madonna label, a studio renowned for its focus on the "mature woman" (jukujo) genre. The film features Yumi Kazama, a prominent and long-standing figure in the AV industry known for her versatility and commanding screen presence. The production fits squarely into the studio's aesthetic of high-quality, narrative-driven adult films focusing on older women. suitable for use in technical reports